611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Hot Water Soak May Help Ease Poor Leg CirculationHealth Tip: Understanding RosaceaHealth Tip: Causes of Swollen Lymph NodesAHA News: Study Provides Rare Look at Stroke Risk, Survival Among American IndiansCDC Opens Emergency Operations Center for Congo Ebola OutbreakScared Safe: Pics of Sun's Damage to Face Boost Sunscreen UseNo Needle Prick: Laser-Based Test Hunts Stray Melanoma Cells in BloodBats Are Biggest Rabies Danger, CDC SaysEmgality Receives First FDA Approval for Treating Cluster HeadacheZerbaxa Approved for Hospital-Acquired Bacterial PneumoniaBlood From Previously Pregnant Women Is Safe for Donation: StudyStudy Refutes Notion That People on Warfarin Shouldn't Eat Leafy GreensCancer Survivors Predicted to Top 22 Million by 2030Your Guide to a Healthier Home for Better Asthma ControlHigh Blood Pressure at Doctor's Office May Be More Dangerous Than SuspectedAHA News: 3 Simple Steps Could Save 94 Million Lives WorldwideHealth Tip: Dealing With Motion SicknessHealth Tip: Symptoms of MeningitisRace Affects Life Expectancy in Major U.S. CitiesVitamin D Supplements Don't Prevent Type 2 Diabetes: StudyChickenpox Vaccine Shields Kids From Shingles, TooWhooping Cough Vaccine Effectiveness Fades With Time: StudyOpioids Put Alzheimer's Patients at Risk of Pneumonia: StudyHealth Tip: Early Signs of Lyme DiseaseHealth Tip: Hiccup Home RemediesSheep Study Shows a Stuffy Side Effect of VapingShould Air Quality Checks Be Part of Your Travel Planning?Health Tip: Preventing Swimmer's EarHeartburn Drugs Again Tied to Fatal RisksHealth Tip: Nasal Spray SafetyFDA Approves First Drug to Help Tame Cluster HeadachesMany Dietary Supplements Dangerous for TeensAverage American Ingests 70,000 Bits of Microplastic Each YearFalls Are Increasingly Lethal for Older AmericansChicken No Better Than Beef for Your Cholesterol?Another Use for Beta Blockers? Curbing A-fibCaffeine, Nicotine Withdrawal Can Cause Problems in the ICU: StudyYounger Gout Patients Have Higher Odds for Blood ClotsFDA Approves First Test for Zika in Human BloodCDC Warns Again of Salmonella From Pet HedgehogsWhy Some Kids With Eczema Are at Higher Allergy RiskMany Heart Failure Patients Might Safely Reduce Use of DiureticsU.S. Measles Cases for 2019 Already Exceed All Annual Totals Since 1992: CDCForget Fasting Before That Cholesterol TestU.S. Cancer Cases, Deaths Continue to Fall'Controlled Burns' Better for Kids' Health Than Wildfires: StudyHighly Processed Diets Tied to Heart Disease, Earlier DeathHealth Tip: Signs of Irritable Bowel SyndromeA Less Invasive Fix Works Well for Abdominal AneurysmFace Transplants Improve Lives Years Later
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Emgality Receives First FDA Approval for Treating Cluster Headache


HealthDay News
Updated: Jun 11th 2019

new article illustration

TUESDAY, June 4, 2019 (HealthDay News) -- The U.S. Food and Drug Administration granted Emgality (galcanezumab-gnlm) solution the first approval for treating episodic cluster headache, the agency announced yesterday.

Previously approved for preventive treatment of migraine in adults, Emgality is administered through patient self-injection. The recommended dosage of Emgality for treatment of episodic cluster headache is 300 mg administered as three 100-mg injections at the initial onset of cluster headaches and then monthly doses of 120 mg until the end of the cluster period.

The drug's approval for treatment of episodic cluster headache was based on a clinical trial of 106 patients. At three weeks, patients taking Emgality had 8.7 fewer weekly cluster headache attacks from baseline compared with 5.2 fewer attacks for patients who were taking placebo.

Injection site reactions were the most commonly reported side effect. Emgality puts patients at risk for hypersensitivity reactions and is contraindicated in patients with a serious hypersensitivity to galcanezumab-gnlm. The FDA states that patients should discontinue use if they experience such a reaction; hypersensitivity reactions could occur days after administration and could last for a prolonged period of time.

Approval was granted to Eli Lilly.

More Information